Glaxosmithkline and Galapagos Enter Strategic Alliance to Develop Novel Antibacterials and Antivirals
News Dec 11, 2007
GlaxoSmithKline will participate in the alliance through its Infectious Diseases Centre of Excellence for Drug Discovery (ID CEDD). Under the terms of the agreement, Galapagos will grant GlaxoSmithKline options to license product candidates that are directed against up to six anti-infective discovery targets.
Galapagos will be responsible for the discovery and development of natural product small molecule drug candidates through to clinical Proof of Concept, at which point GSK will have exclusive option to license each compound for further development and commercialization on a worldwide basis.
The alliance will utilize the natural product compound collection and chemistry capabilities of BioFocus DPI, Galapagos' services division. Galapagos will have the right to further develop and commercialize compounds for which GSK does not exercise its option.
Galapagos will receive total upfront fees of up to €3.5 million from GSK, depending on the total number of programmes within the collaboration. Galapagos could be eligible to receive up to €95 million in upfront fees, development and regulatory milestones payments for each product candidate.
If a product is commercialized, Galapagos may receive up to €120 million for achievement of specific sales milestones. Galapagos is also eligible to receive up to double-digit royalties on worldwide sales of alliance products.
"This is our first alliance outside bone and joint diseases. It shows that Galapagos can generate significant business in new therapeutic areas," said Onno van de Stolpe, Galapagos' CEO.
"The alliance will rely heavily on BioFocus DPI's natural product discovery capabilities. This alliance fits within our strategy of executing risk/reward sharing deals with big pharma and at the same time underscores our M&A approach and successful integration of DPI into the BioFocus service division."
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE